• TenNor Therapeutics

  Participated · Series B · Sep 2016

  TenNor Therapeutics is a clinical-stage company in Suzhou, China, focused on discovery and development of differentiated new drug products against bacterial infection and metabolism-related diseases. It possesses a multi-targeting drug conjugate technology platform and strong new drug development portfolio with global IP protection. Several products are currently in late-stage clinical development targeting H. pylori infection, medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company raised over RMB300M in a Series E financing; backers included AMR Action Fund, Zhongshan Venture Capital and other existing investors. Proceeds will support development and the pursuit of regulatory approval in China for rifasutenizol, which could become the first new drug developed specifically for Helicobacter pylori infection in more than 30 years. Led by founder and CEO Dr. Zhenkun Ma, TenNor says it is committed to addressing unmet needs and providing safe, effective therapies for patients in China and globally. TenNor Therapeutics is a Suzhou, China–based clinical-stage company focused on developing dual-acting antibiotics. Its lead candidate is TNP-2092, an oral capsule designed as a locally acting gastrointestinal antibiotic with potential to improve treatment of Helicobacter pylori and other gastrointestinal bacterial infections. The compound is currently in early-stage clinical development. TenNor intends to use the Series B proceeds to advance TNP-2092 into Phase III trials, move a second product to clinical proof-of-concept, and advance a third into Phase I. Founded in 2013 in BioBAY by Dr. Zhenkun Ma, the company is advancing several dual-acting molecules through preclinical and clinical stages. TenNor has acquired patents and other assets from Cumbre IP Venture and patents from the TB Alliance and raised $25M in this Series B.

• Innovent Biologics

  Participated · Series C · Jan 2015

  Innovent Biologics is a Hong Kong-based biotech that develops and manufactures affordable complex biopharmaceutical products. Founded in August 2011 by Dr. Michael Yu, the company has built a portfolio targeting cancer, ophthalmology, autoimmune disorders, and cardiovascular diseases. It currently has 16 molecules in research, seven in clinical development, four in Phase III and one with a BLA submitted to the CFDA. Five molecules have been selected under the national mega innovative program and one received a precision medicine research grant under China's National Key R&D Plan. Innovent has a large-scale manufacturing base compliant with CFDA, FDA and EMA GMP standards. The company intends to use the funds to speed up and expand clinical programs and to build a commercial team. Innovent Biologics is a Shanghai, China–based biopharmaceutical company dedicated to the discovery, development, manufacturing and commercialization of biologics. Founded in August 2011 by Michael Yu, Ph.D., the company has built a portfolio of 12 product candidates targeting cancer, autoimmune disorders, ophthalmology and cardiovascular diseases. Innovent has filed eight IND applications and has four products in clinical development, three of which are in phase 3 trials. The company operates under rigorous cGMP requirements and is expanding its manufacturing capacity. It intends to use new funding to continue development of innovative biopharmaceutical products, expand manufacturing, and support ongoing operations. Innovent Biologics is a Shanghai-based biopharmaceutical company dedicated to the development and manufacturing of complex biologics. Led by co-founder, president and CEO Michael Yu, the company is advancing an internal pipeline of eight antibody products, including one approved IND and four additional filed applications. Innovent aims to market its portfolio in the Chinese market and internationally while meeting EMEA and FDA/cGMP standards. Its strategy combines advancing proprietary biologic drugs with establishing in- and out-licensing agreements with global pharmaceutical and biotech companies. The company plans to use newly raised funds to advance its pipeline and grow operations. Innovent raised capital to support these plans and expand its development and manufacturing activities.

• Hua Medicine

  Participated · Series B · Jan 2015

  Hua Medicine is a Shanghai-based, clinical-stage drug development company focused on novel therapies for Type 2 diabetes and levodopa-induced dyskinesia in Parkinson’s disease. The company has worldwide rights to two novel assets, the most advanced being dorzagliatin (HMS5552). Dorzagliatin is described as a first-in-class, 4th-generation glucokinase activator that aims to treat impaired blood glucose sensor function. The drug is in two Phase III trials in China: a monotherapy study and a combination therapy study with metformin. Hua announced a combined Series D & Series E financing intended to fully fund completion of those Phase 3 trials and a commercial launch in China. The company was founded by entrepreneurs and international investment firms and positions dorzagliatin as a potential disease-modifying treatment for Type 2 diabetes. Hua Medicine is a clinical-stage, innovative drug development company focused on novel therapies for the treatment of diabetes and central nervous system disorders. Its lead program is HMS5552, a new 4th-generation glucokinase activator (GKA) for type 2 diabetes. The company plans to use the new financing to complete long-term Phase 2 clinical trials and to accelerate Phase 3 development of HMS5552, alongside advancing additional novel assets in its pipeline. Hua is led by CEO Li Chen and is based in Shanghai, China. It expects to finish a multicenter, 12-week Phase 2 trial of HMS5552 in diabetic patients by mid-year, with topline results available by the end of 2016. Hua Medicine is a Shanghai, China–based clinical-stage biotech led by Dr. Li Chen developing novel therapies for Type 2 diabetes and CNS disorders. Its most advanced program is HMS5552 (Sinogliatin), an oral 4th‑generation glucokinase activator (GKA) about to enter Phase 2 trials in China. The company has also internally developed earlier-stage CNS compounds targeting a validated CNS target for indications including Parkinson’s disease–associated dyskinesia and depressive disorder. Hua recently closed a $25M Series B to fund clinical and preclinical programs. Planned uses of proceeds include catalyzing Phase 2 development of HMS5552, advancing GKA therapies in the U.S., developing an IND candidate for a novel CNS asset, and sponsoring long‑term preclinical studies to prepare for future Phase 3 trials.

• MID Labs

  Led · Equity · Oct 2014

  MID Labs Ltd. is focused on developing novel products for vitreoretinal surgery, including vitrectors. The company invented tools for modern vitrectomy and supplies its MID Labs-branded product line to more than 30 countries. MID Labs also provides products and contract manufacturing services to corporate customers. Founded by Dr. Carl Wang in 1981 and based in San Leandro, Calif., the company has a long history in the ophthalmic field. MID Labs says it will use proceeds from the financing to expand development and production capacity in the U.S. and China and to broaden its product lines and commercialization capabilities globally. The company emphasizes technology leadership, precision, performance, and quality in its ophthalmic products.

No current team members are available.